Jacquelyn Horsington

Dr. Jacquelyn Horsington

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2016 in BMC Genomics
Verified
Journal Article
Open access
PDF file
PVPaola K. Vaz
Paola K. Vaz
NJNatalie Job
Natalie Job
JHJacquelyn Horsington
Jacquelyn Horsington
NFNino Ficorilli
Nino Ficorilli
MSMichael J. Studdert
Michael J. Studdert
JDJoanne M. Devlin
Joanne M. Devlin
Felid herpesvirus 1 (FHV-1) causes upper respiratory tract diseases in cats worldwide, including nasal and ocular discharge, conjunctivitis and oral ulceration. The nature and severity of disease can vary between clinical cases. Genetic determinants of virulence are likely to contribute to differences in the in vivo phenotype of FHV-1 isolates, but to date there have been limited studies investigating FHV-1 genetic diversity. This study used next generation sequencing to compare the genomes of contemporary Australian clinical isolates of FHV-1, vaccine isolates and historical clinical isolates, including isolates that predated the introduction of live attenuated vaccines into Australia. Analysis of the genome sequences aimed to assess the level of genetic diversity, identify potential genetic markers that could influence the in vivo phenotype of the isolates and examine the sequences for evidence of recombination. The full genome sequences of 26 isolates of FHV-1 were determined, including two vaccine isolates and 24 clinical isolates that were collected over a period of approximately 40 years. Analysis of the genome sequences revealed a remarkably low level of diversity (0.0–0.01 %) between the isolates. No potential genetic determinants of virulence were identified, but unique single nucleotide polymorphisms (SNPs) in the UL28 and UL44 genes were detected in the vaccine isolates that were not present in the clinical isolates. No evidence of FHV-1 recombination was detected using multiple methods of recombination detection, even though many of the isolates originated from cats housed in a shelter environment where high infective pressures were likely to exist. Evidence of displacement of dominant FHV-1 isolates with other (genetically distinct) FHV-1 isolates over time was observed amongst the isolates obtained from the shelter-housed animals. The results show that FHV-1 genomes are highly conserved. The lack of recombination detected in the FHV-1 genomes suggests that the risk of attenuated vaccines recombining to generate virulent field viruses is lower than has been suggested for some other herpesviruses. The SNPs detected only in the vaccine isolates offer the potential to develop PCR-based methods of differentiating vaccine and clinical isolates of FHV-1 in order to facilitate future epidemiological studies.

14 January 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
ADAldo Dekker
Aldo Dekker
BBBeatriz Sanz Bernardo
Beatriz Sanz Bernardo
NBNagendrakumar Singanallur Balasubramanian
Nagendrakumar Singanallur Balasubramanian
ALAnna Ludi
Anna Ludi
JHJacquelyn Horsington
Jacquelyn Horsington
WVWilna Vosloo
Wilna Vosloo
Since 2015, outbreaks of foot-and-mouth disease (FMD) in the Middle East have been caused by a new emerging viral lineage, A/ASIA/G-VII. Invitro vaccine matching data indicated that this virus poorly matched (low r1-value) with vaccines that were being used in the region as well as most other commercially available vaccines. The aim of this study was to assess the performance of two candidate vaccines against challenge with a representative field virus from the A/ASIA/G-VII lineage. The results from an initial full dose protection study provided encouraging data for the A/MAY/97 vaccine, while the A22/IRQ/64 vaccine only protected 2/7 vaccinated animals. In view of these promising results, this vaccine was tested in a potency test (PD50) experiment in which 5 cattle were vaccinated with a full dose, 5 cattle with a 1/3 dose and 5 cattle with a 1/9 dose of vaccine. At 21 days post vaccination these vaccinated cattle and 3 control cattle were challenged intradermolingually with a field isolate from the A/ASIA/G-VII lineage. The intra-serotype heterologous potency test resulted in an intra-serotype heterologous potency of 6.5 PD50/dose. These data support previous studies showing that a high potency emergency vaccine can protect against clinical disease when challenged with a heterologous strain of the same serotype, indicating that not only the r1-value of the vaccine, but also the homologous potency of a vaccine should be taken into account when advising vaccines to control an outbreak.

10 February 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
NBNagendrakumar Singanallur Balasubramanian
Nagendrakumar Singanallur Balasubramanian
ADAldo Dekker
Aldo Dekker
PEPhaedra L. Eblé
Phaedra L. Eblé
FHFroukje van Hemert-Kluitenberg
Froukje van Hemert-Kluitenberg
KWKlaas Weerdmeester
Klaas Weerdmeester
WVWilna Vosloo
Wilna Vosloo
The continuous emergence of foot-and-mouth disease virus (FMDV) serotype A variants in South East Asia is of concern for international FMDV antigen banks, especially when in vitro tests predict a low antigenic match. A vaccination-challenge study was performed by using two emergency FMDV vaccines with A22 Iraq 64 (A22 IRQ) and A Malaysia 97 (A MAY 97) strains, against challenge with a variant strain of FMDV A/Asia/G-IX/SEA-97 lineage at 7- and 21-day post-vaccination (dpv). At 7 dpv, three of five female calves vaccinated with A MAY 97 and four of five vaccinated with A22 IRQ did not show lesions on the feet and were considered protected, while at 21 dpv all five calves were protected with each vaccine, indicating equal efficacy of both vaccine strains. Calves were protected despite relatively low heterologous neutralizing antibody titers to the challenge virus at the time of challenge. All the calves developed antibodies to the non-structural proteins, most likely due to the direct intradermolingual (IDL) inoculation. Only one calf from the A MAY 97-7 group had infectious virus in the serum 1–3-day post-challenge (dpc), while no virus could be isolated from the serum of cattle challenged on 21 dpv. The virus could be isolated from the oral swabs of all calves, 1–7 dpc with viral RNA detected 1–10 dpc. Nasal swabs were positive for virus 1–6 dpc in a small number of calves. The time between vaccination and infection did not have an impact on the number of animals with persistent infection, with almost all the animals showing viral RNA in their oro-pharyngeal fluid (probang) samples up to 35 dpc. Despite the poor in vitro matching data and field reports of vaccine failures, this study suggests that these vaccine strains should be effective against this new A/Asia/G/SEA-97 variant, provided they are formulated with a high antigen dose.

1 September 2017 in Vaccine
Verified
Journal Article
Closed access
JHJacquelyn Horsington
Jacquelyn Horsington
CPClaudia Beascoechea Perez
Claudia Beascoechea Perez
EMEduardo Maradei
Eduardo Maradei
SNSabrina Galdo Novo
Sabrina Galdo Novo
Jose L GonzalesJose L Gonzales
Jose L Gonzales
WVWilna Vosloo
Wilna Vosloo

28 July 2021 in Animals
Verified
Journal Article
Open access
PDF file
JHJacquelyn Horsington
Jacquelyn Horsington
MWMaarten Witvliet
Maarten Witvliet
AJAntonius A. C. Jacobs
Antonius A. C. Jacobs
RSRuud Segers
Ruud Segers
The combined application of vaccines in swine offers many benefits, including reduced time and labour costs, and improved animal welfare, due to fewer injections and manipulations. This study investigated if simultaneous intradermal vaccinations against porcine circovirus 2, porcine reproductive and respiratory syndrome virus, Mycoplasma hyopneumoniae, and Lawsonia intracellularis, using a specialised needle-free applicator would confer comparable protection against experimental infection compared to the single vaccines. In all cases, the administration of the vaccines together was as efficacious as the administration of the vaccines alone, significantly reducing clinical signs associated with each of the four pathogens.

1 October 2018 in Vaccine
Verified
Journal Article
Closed access
JHJacquelyn Horsington
Jacquelyn Horsington
CNCharles Nfon
Charles Nfon
Jose L GonzalesJose L Gonzales
Jose L Gonzales
NSNagendrakumar Singanallur
Nagendrakumar Singanallur
HBHilary Bittner
Hilary Bittner
WVWilna Vosloo
Wilna Vosloo